# A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Source: https://onco.cc/trials/nct06247995/  
OnCo record `nct06247995` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. is a phase 1/2 interventional study registered as NCT06247995 by Novartis Pharmaceuticals, with 20 participants enrolled, started 2024-08-14 and due to reach its primary completion in 2027-04-14. Interventions recorded: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB and Capecitabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06247995
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06247995: https://clinicaltrials.gov/study/NCT06247995

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct06247995.json